Core Thesis - Tempus AI, Inc. (TEM) is positioned as a long-term growth opportunity at the intersection of oncology, data compounding, and artificial intelligence, with a focus on building the largest library of clinical and molecular data [2][4]. Business Model and Data Flywheel - The company is creating a powerful data flywheel where increased usage by oncologists enhances the database, leading to improved AI-driven insights that attract pharmaceutical companies for drug discovery [3][4]. - Tempus' model is designed for decades of intrinsic value growth, with applications in pathology and cardiology expected to transition from experimental to industry standard, establishing the company as a generational asset in healthcare AI [4]. Investment Strategy - A strategic approach involves selling 1,500 January 2027 $50 put contracts at $8.35, setting a target entry price of $41.65, which offers a significant margin of safety compared to current valuations [3][5]. - This disciplined method allows for capturing long-term upside while mitigating short-term volatility, ensuring ownership occurs at an attractive risk-reward point [5][6]. Financial Performance and Projections - Previous analyses indicated strong revenue and EBITDA growth projections of over 20% over two years, with an attractive valuation at 6x NTM sales [7]. - Since the last coverage, TEM's stock price has appreciated by 18.89%, reflecting positive market sentiment [7].